Abstract:Vestibular schwannomas (VS) arise from myelinating Schwann cells of CN VIII and are associated with severe morbidity due to local tumor growth. Sporadic and neurofibromatosis type 2 (NF2) associated VS are both characterized by NF2 (merlin) loss but the mechanisms remain unexplored. Using a multiomic approach, we dissected the role of NF2 loss in VS tumor formation and proliferation. We obtained surgical samples from 15 patients undergoing surgery for VS (sporadic, n=4; NF2, n=9), and performed single-cell or single-nucleus RNA sequencing (scRNAseq, n=4; snRNAseq, n=15), transposase-accessible chromatin (snATAC-seq, n=9), whole exome (n=12), and bulk DNA methylation assays (n=15). Transcription factor binding was assayed with ChIPseq. We validated our key findings with immunoblot, ELISA, RNAscope (n=8), and multiplex immunocytochemistry (mIHC; n=8). NF 2 fl/fl ;Periostin-Cre + mice versus their Cre - control littermates treated with novel inhibitors of TEAD auto-palmitoylation (VTs). We mapped the VS transciptome and identified canonical Schwann cells, macrophages, T-cells and endothelial cells. Using the cells that had Chr22 loss (second hit deletions at the NF2 locus), we generated a NF2loss gene signature. We then identified Schwann(NF2loss) cells in all tumors, and found these enriched for YAP1/TAZ-TEAD , NRG1 , and HIF-1α signaling pathways. Schwann(NF2loss) cells showed increased TEAD1 expression and chromatin accessibility for TEAD family transcription factor motifs. TEAD1 binding was observed at promoters of genes including VEGFA , EGFR , with strong enrichment for mitogenic pathways. We also found that VEFGA expression was restricted to Schwann(NF2loss) cells, and confirmed this with RNAscope and mIHC. Schwann(NF2loss) cells were key regulators of macrophages (M2-subtype, tissue resident) through M-CSF/IL-34 signaling. NF 2 fl/fl ;Periostin-Cre + mice showed increased VEGFA expression, and that was reversible by TEAD inhibition in-vivo with VTs. We report that Schwann(NF2loss) cells are key tumor drivers in VS. These cells are highly proliferative (YAP/TAZ-TEAD axis), drive angiogenesis (VEGFA expression), and promote tumor mass accretion (macrophage influx via M-CSF/IL-34 pathway) that can all be targeted via TEAD inhibition.

Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated Schwann cell proliferation in human.

Merlin Cooperates with Neurofibromin and Spred1 to Suppress the Ras-Erk Pathway.

The NF2 Tumor Suppressor Merlin Interacts with Ras and RasGAP, Which May Modulate Ras Signaling

Role of Merlin/NF2 inactivation in tumor biology

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

Molecular Insights and Therapeutic Avenues

Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2

A Novel NF2 Mutation Associated with Neurofibromatosis Type 2 Causes Aberrant Splicing and Phase Separation

A Novel Alternative Splicing Isoform of NF2 Identified in Human Schwann Cells.

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

Synergistic Effect of Nutlin-3 Combined with MG-132 on Schwannoma Cells Through Restoration of Merlin and P53 Tumour Suppressors

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma

The Phosphorylation Status of Merlin in Sporadic Vestibular Schwannomas.

Csig-19. Identification And Targeting Of Tumor Driver Schwann(Nf2Loss) Cells In Sporadic And Nf2-Related Vestibular Schwannomas

Merlin regulates signaling events at the nexus of development and cancer

Tmod-30. Disruption Of Normal Radial Glia Development In An Nf2-Altered Neuroepithelial Stem Cell Model

CSIG-37. MERLIN S13 DEPHOSPHORYLATION DRIVES MENINGIOMA WNT SIGNALLING AND CELL PROLIFERATION

Combined Mtor/mek Inhibition Prevents Proliferation and Induces Apoptosis in NF2-mutant Tumors

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis